Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O75081

UPID:
MTG16_HUMAN

ALTERNATIVE NAMES:
MTG8-related protein 2; Myeloid translocation gene on chromosome 16 protein; Zinc finger MYND domain-containing protein 4

ALTERNATIVE UPACC:
O75081; D3DX78; O60615; O60616; O60617; O75082; O75107; O75108; Q0P5Z6; Q6P5W6

BACKGROUND:
The Protein CBFA2T3, with alternative names such as MTG8-related protein 2 and Zinc finger MYND domain-containing protein 4, serves as a transcriptional corepressor. It is pivotal in transcriptional repression, HIF1A protein degradation, and the regulation of glycolytic genes. Isoform 2 of this protein functions as an A-kinase-anchoring protein, showcasing its versatility in cellular functions. Its role extends to influencing the proliferation and differentiation of erythroid progenitors and aiding in granulocyte differentiation.

THERAPEUTIC SIGNIFICANCE:
The exploration of Protein CBFA2T3's functions offers promising avenues for therapeutic development. Given its significant role in transcriptional repression, energy metabolism, and cell differentiation, targeting this protein could lead to innovative treatments for conditions associated with these biological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.